Evidence map›Paper›PMID 29155891›Full record

ArticlePloS one2017

The burden of gynecomastia among men on antiretroviral therapy in Zomba, Malawi.

Victor Singano, Alemayehu Amberbir, Daniela Garone, Christopher Kandionamaso, Jack Msonko, Monique van Lettow, Kondwani Kalima, Yamikani Mataka, Gift Kawalazira, Gabriel Mateyu and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Victor SinganoDignitas International, Zomba, Malawi.
Alemayehu AmberbirDignitas International, Zomba, Malawi.
Daniela GaroneDignitas International, Zomba, Malawi.
Christopher KandionamasoDignitas International, Zomba, Malawi.
Jack MsonkoDignitas International, Zomba, Malawi.
Monique van LettowDignitas International, Zomba, Malawi.
Kondwani KalimaDignitas International, Zomba, Malawi.
Yamikani MatakaDignitas International, Zomba, Malawi.
Gift KawalaziraZomba District Health Office, Malawi Ministry of Health, Zomba, Malawi.
Gabriel MateyuDignitas International, Zomba, Malawi.
Aunex KwekwesaDignitas International, Zomba, Malawi.
Alfred MatengeniDignitas International, Zomba, Malawi.
Joep J van OosterhoutDignitas International, Zomba, Malawi.
Dignitas International · MWMinistry of Health · MWPublic Health Ontario · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMany Africans who are on life-saving ART face challenges from a variety of toxicities. After the introduction of a standardized first-line efavirenz-containing ART regimen, reports of gynecomastia appeared in Malawian popular media, however data on the prevalence and risk factors of gynecomastia from Africa are lacking.

methodsWe conducted a cross-sectional study in males ≥18 years registered on ART at the HIV clinic in Zomba Central Hospital. Men who reported to have ever experienced breast or nipple enlargement received a standard questionnaire and underwent physical examination. Questions included perceptions and concerns about gynecomastia. Clinicians confirmed the presence and severity of gynecomastia. Routinely collected data on current and previous ART regimens, CD4 count, WHO clinical stage, anthropometric measurements and history of tuberculosis were extracted from the electronic database.

resultsWe enrolled 1,027 men with median age 44 years (IQR: 38-52). The median ART duration was 57 months (IQR: 27-85); 46.7% were in WHO stage III/IV at ART initiation, 88.2% had exposure to efavirenz and 9% were overweight or obese. The prevalence of self-reported gynecomastia was 6.0% (62/1027) (95%-CI: 4.7-7.7%). Of men with gynecomastia 83.6% reported nipple enlargement and 98.4% enlarged breasts (85.5% bilateral). One-third said they had not reported gynecomastia to a health care worker. Over three-quarters mentioned that gynecomastia was an important or very important problem for them, while more than half were embarrassed by it. On examination gynecomastia was present in 90% (confirmed gynecomastia prevalence 5.5%; 95%-CI: 4.2-7.0%) and 51.8% had severity grade III or IV. History of tuberculosis treatment was independently associated with self-reported gynecomastia, adjusted OR 2.10 (95%-CI: 1.04-4.25).

conclusionsThe burden of gynecomastia among men on ART in Malawi was higher than previously reported, and was associated with adverse psychological consequences, calling for increased awareness, a proactive diagnostic approach and diligent clinical management.

Indexed as

AdultAlkynesAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveBenzoxazinesCross-Sectional StudiesCyclopropanesGynecomastiaHIV InfectionsHumansMalawiMaleMiddle AgedNipplesObesityPrevalenceAlkynesAnti-HIV AgentsBenzoxazinesCyclopropanesefavirenz

Identifiers

PMID29155891
PMCPMC5695797
OpenAlexW2770742949

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.